Bristol Myers Squibb provides its 2024 non-GAAP EPS guidance range of $7.10 – $7.40. Total 2024 revenues are expected to increase by low single-digits; Excluding foreign exchange, total revenues are expected to increase by low single-digits. Non-GAAP Gross margin is expected to be approximately 74%. Non-GAAP Operating expenses are expected to increase by low single-digits. Other Income/(Expense) is expected to be approximately $250M. “The 2024 financial guidance excludes the impact of any potential future strategic acquisitions, including the announced planned acquisitions of RayzeBio and Karuna, divestitures, specified items, and the impact of future Acquired IPRD charges,” the company stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- U.S. sends offers for drugs selected for price negotiations, NY Times says
- BMY Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 2seventy Bio to focus on Abecma commercialization with Bristol Myers Squibb
- Bristol Myers’ application for Breyanzi in lymphoma accepted in U.S. and Japan
- Bristol Myers announces first disclosure of data from Phase 3 CheckMate -67T
